Bioscience ClubhouseCT

//Bioscience ClubhouseCT

Bioscience ClubhouseCT Presents: A University-Public Company Joint Venture Success Story

On Tuesday, June 9th, the Founder, CEO, and Executive Chairman of Novogen, Dr. Graham Kelly, spoke on behalf of his company’s success. Novogen is an US-Australian public drug discovery company that has recently teamed with the Yale School of Medicine. Together, they call themselves CanTx. To date, cancer research companies strive to develop chemotherapies that target the body of a tumor. The body consists of rapidly diving daughter cells. These cells are derived from slow-dividing tumor-initiating stem cells, which are resistant to chemo- and radiotherapies. CanTx’s mission goes beyond today’s most efficient chemotherapy techniques and targets the cancer stem cells. [...]

Connecticut Synthetic Chemistry Start-Up Uses a Practical Business Model to Develop Drugs

Our September 24th’ Bioscience ClubhouseCT was the kick-off of the Fall season. The Study in New Haven provided a very fine venue, with pizza by Aerotek. The atmosphere at this ClubhouseCT felt like our community has joined together to give this event momentum. It was wonderful to feel the enthusiasm and interest in the room as Uday Khire shared his experiences using the platform of synthetic organic chemistry, especially in area of macrocyclics, to build two biotech companies, Cheminpharma, and its spin out Allomek. Clearly Uday is quite a determined entrepreneur, passionate about using chemistry to make new medicines. Carefully [...]

By |September 26th, 2014|Bioscience ClubhouseCT, Event Highlights|0 Comments

Meet and Greet at the Town of Branford

On July 22nd, 2014, over 80 people from the Connecticut bioscience community gathered at the town of Branford for the CURE Bioscience ClubhouseCT “Meet and Greet” event, which featured eight Branford-based bioscience companies. Susan Froshauer, CEO of CURE, Usha Pillai, founder of the Bioscience ClubhouseCT, together with James Cosgrove, First Selectman of Branford, delivered the opening remarks. Froshauer and Pillai welcomed the attendees and described the CURE Bioscience ClubhouseCT’s mission of cultivating entrepreneurship and developing the start-up ecosystem in Connecticut. Cosgrove introduced the vibrant business environment in Branford and invited companies to move in to the town. Eight speakers then [...]

By |July 24th, 2014|Bioscience ClubhouseCT, Event Highlights|0 Comments

Fighting Against Heart Failure-The Start-up Story of Cornovus Pharmaceuticals

On June 16th, CURE Bioscience ClubhouseCT presented the start-up story of Cornovus Pharmaceuticals at UConn Cell and Genome Sciences Building. Faced with the rising prevalence of heart failure related to the aging population, Cornovus is committed to discovering and developing novel treatments to fight the battle against heart failure. James Heym, Senior Director of Cornovus, together with Julie Olson, CEO of Cornovus, spoke about the company’s scientific foundation and its business model at the event. Heart failure represents an end-stage phenotype of a number of different cardiovascular diseases. Despite its poor prognosis and significant healthcare cost due to hospitalization, there [...]

By |June 22nd, 2014|Bioscience ClubhouseCT, Event Highlights|0 Comments

The Impact of Big Data and Analytics on Pharmaceutical R&D-The SystaMedic Approach

Big data and analytics are a major catalyst in the pharmaceutical R&D revolution. The explosion of data created across the health care sectors provides a great opportunity for accelerating innovation. A compelling question currently facing the pharmaceutical industry is how to effectively utilize this data to create value. On May 12th, CURE Bioscience ClubhouseCT showcased SystaMedic’s novel cause-effect analysis platform that can efficiently predict the probability of R&D success. SystaMedic Inc., founded in 2009, consists of twelve former Pfizer leaders and scientists with an average of 20+ years pharmaceutical R&D experience with multi-disciplinary expertise including medicinal chemistry, prodrug design, synthesis [...]

By |May 22nd, 2014|Bioscience ClubhouseCT, Event Highlights|0 Comments

CURE Bioscience ClubhouseCT Presented the Start-up Story of Bioarray Therapeutics

On April 16th, CURE Bioscience ClubhouseCT invited Marcia Fournier, CEO of Bioarray Therapeutics, to speak at the spacious atrium on the Pfizer Groton campus. Aiming to tackle the “trial and error chemotherapy”problem and to help oncologists choose the right therapy, Bioarray develops personalized diagnostic tests to assess the effectiveness of breast cancer treatment for a given patient. As a molecular biologist with years of experience in cancer research, Marcia Fournier highlighted three essential elements of Bioarray: think differently, establish mutually beneficial partnerships and build a strong team. In contrast to most studies that focus on the unhealthy cancer patient populations, [...]

By |April 24th, 2014|Bioscience ClubhouseCT|0 Comments